—

Sanofi

Q2 2026 13F Holdings

  • Location
    paris, I0
  • Num holdings

    10

  • Value ($000)

    $534,042

  • Date Filed
    07/28/2026
  • Form type
    13F-HR
  • CIK
    0001121404
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2026 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

MeiraGTx Holdings plc

COM
G59665102
$164.79M
31 %

12,197,737

I
INBX

Inhibrx Biosciences, Inc.

COM
45720N103
$109.71M
21 %

1,157,926

N
NVV1

Novavax

COM NEW
670002401
$64.81M
12 %

6,880,481

A
ANAB

AnaptysBio

COM
032724106
$55.48M
10 %

821,917

---

Odyssey Therapeutics Inc.

COMMON STOCK
67613T104
$37.27M
7 %

1,991,918

---

Agomab Therapeutics NV

SPONSORED ADS
00860C102
$36.12M
7 %

2,783,096

---

MapLight Therapeutics Inc.

COM
56565P103
$32.69M
6 %

912,041

---

First Tracks Biotherapeutics Inc.

ORD SHS
337185102
$16.54M
3 %

821,917

I
IMRX

Immuneering Corp

CLASS A COM
45254E107
$13.52M
3 %

2,708,559

Q
QTTB

Q32 Bio Inc.

COM
746964105
$3.11M
1 %

244,083

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 10